Collectively, the findings generated in this study show ARQ-197 may be an effective anti-tumour agent in the treatment of MM as others have shown, but more importantly may also prevent myeloma-induced bone loss both as an indirect consequence of reduced tumour load and as a direct consequence of blockade of HGF induced inhibition of bone formation. Here, HGF is linked to plasma cell myeloma.